Biomedical subjects
Publications and source records attributed to N Chatterjie.
The CH2 proton NMR linewidths of sn-3 and sn-1 dipalmitoyl phosphatidylcholine respond differently to the addition of cholesterol to the lipid vesicles. This result points to a stereospecific phospholipid-cholesterol interaction in the "hydrogen belt" region.
The permeability of an N-oleoyldihydrosphingomyelin bilayer against glycerol was similar to that of a bilayer of phosphatidylcholine with identical effective hydrophobic chain length. Cholesterol at 1:1 molar ratio reduced the permeability, and also reduced the energy of activation of glycerol penetration, an effect not found for diesterphosphatidylcholine with cholesterol. The higher level of the ground state of the entropy of activation for permeability can be interpreted in terms of a hydrogen belt model which postulates lipid-lipid hydrogen bonding in membranes and explains the effect found as a disturbance of the hydrogen belt structure. Dihydrosphingomyelin can be considered to function as an "extender" in the hydrogen belt network.
Explore the source record for details and available documents.
A method employing solvent extraction and gas-liquid chromatography has been developed for the quantitative determination of acetylmethadol simultaneously with its two major biotransformation products, noracetylmethadol and dinoracetylmethadol. Noracetylmethadol and dinoracetylmethadol are analyzed following their conversion to the corresponding amides. The amide structure is confirmed by the use of chemical ionization mass spectroscopy and infrared spectroscopy. The method can be used to determine the concentration of acetylmethadol and these compounds in plasma samples from acetylmethadol maintenance subjects. Methadol and normethadol do not attain neasurable plasma levels. Urine contains predominantly noracetylmethadol and dinoracetylmethadol. Evidence was also obtained for the urinary excretion of acetylmethadol, methadol and normethadol. A mean quantity equal to 28% of the administered dose was excreted in the urine of a 48-h dosing interval as acetylmethadol and metabolites.
The narcotic antagonists naltrexone (1a) and naloxone (2a) were stereospecifically reduced to the corresponding 6beta-hydroxy epimers 1b and 2b, respectively, with formamidinesulfinic acid in an aqueous alkaline medium. The reaction products were obtained with no detectable quantity of the 6alpha epimers 1c and 2c. The products 1b and 2b were formed in yields of 88.5 and 40%, respectively, and characterized by spectral methods. Compared to 1a and 2a, the stereospecific reduction products 1b and 2b and their 6alpha epimers 1c and 2c are all significantly less potent as narcotic antagonists in mice. Only 1c and 2c also possess antinociceptive activity.
A facile N-demethylation of the narcotic analgesic, alpha-1-acetylmethadol, was accomplished by allowing it to react with mercuric acetate under reflux in dilute acetic acid. The product, alpha-1-noracetylmethadol, was isolated as the hydrochloride in 50% yield. Methadone, when allowed to react with mercuric acetate under the same conditions, did not undergo N-demethylation and was recovered unchanged.
A rabbit liver enzyme system was used to produce the 6beta-OH reduced metabolites of naloxone and naltrexone. GC analysis indicated the presence of some 6alpha-OH metabolite in these samples. The narcotic antagonist activity of these 6beta-OH metabolite samples were compared to naloxone, naltrexone and standard 6alpha-OH naltrexone (EN-2260A) using the jumping response of morphine pellet implanted mice. For the naloxone series, the potencies were: Naloxone greater than EN 2265A greater than 6 beta-OH maloxone. For the naltrexone series: Naltrexone greater than EN 2260A greater than beta-OH naltrexone. The low potency of the reduced metabolites the rapid onset of action of the parent compounds militate against the formation of these metabolites contributing substantially to the overall narcotic antagonist action of the parent compounds.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Mexiletine, an antiarrhythmic drug, exerted a protective effect in mice against convulsive seizures induced by electroshock or the chemical convulsant, pentylenetetrazol, and against seizures induced in inbred audiosusceptible mice by a sound signal. Administered in large doses, mexiletine produced a hyperkinetic myoclonic syndrome of 30-60 min duration. The hyperkinesia could be controlled by dimethylaminoethanol, phenobarbital and by an experimental anticonvulsive agent, eboracin.
Explore the source record for details and available documents.